Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects. This study follows the ...
The science fiction trope of humans superpowered by computer and bionic implants is fast becoming a reality, and today, a startup hoping for a role in how that plays out is announcing some funding.
Phantom Neuro, a neurotechnology company that offers a muscle-machine interface for controlling prosthetic limbs and robotic exoskeletons, announced an oversubscribed $19 million Series A funding ...
Hosted on MSN
Neuroplasticity: How Everyday Experiences Influence Brain Function- 6 Exercises To Boost Cognitive Capacity
As I recently stood in a bustling gallery, surrounded by bold colors, vibrant textures, and intriguing sculptures, I was struck by the realization of how much our environment shapes us. Each new sight ...
Shares of Alzamend Neuro, Inc. (ALZN) soared 82% on Thursday afternoon after the company announced the dosing of the first patient in its first Phase II clinical study of AL001 in healthy human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback